Regrettable that BMA let slip medics are excited for new strikes
He told the PA news agency that union members 'could be round the table working together' rather than on picket lines.
Doctors in training, formerly known as junior doctors, are currently being balloted on whether or not to stage further walkouts, with the vote closing on July 7.
Speaking at the BMA's annual representative meeting in Liverpool on Tuesday, Dr Ross Nieuwoudt, co-chair of the union's resident doctors committee, suggested that 'people are excited to go again'.
He then corrected this to 'energised' when pressed.
He said: 'Excited as in energised. Not excited as in looking forward to it.'
Mr Streeting told PA: 'I don't think the resident doctors on the front line are excited by the prospect of strike action.
'I don't think that people want to be out on picket lines.
'And I think it's regrettable that the BMA to be honest let slip that they're feeling excited.'
Previous strikes by resident doctors have taken place 11 times since 2022, leading to almost 1.5 million appointments being cancelled or rescheduled.
Members of the BMA voted to accept a Government pay deal worth 22.3% on average over two years last September.
The Government also committed to working with the union to streamline how resident doctors report any additional hours they work.
Dr Nieuwoudt said on Tuesday that doctors in training 'want to push for change', but 'their cries have fallen on deaf ears'.
He said that while Mr Streeting gave medics 'a good deal that could stop the strike action at the time', which included promises about a 'genuine pathway' towards restoring pay, this has not happened.
Mr Streeting told PA: 'I just remind the BMA that they've got in me, someone who not only wants to work with them, has already worked with them to deliver a 28.9% pay rise for resident doctors for the last three years, and shares their anger about the experiences of frontline resident doctors in terms of how their treated at work.
'Their placements, their rotations, their ability to take time off, the lack of hot food facilities overnight.
'So rather than be out on the picket line, we could be round the table working together to sort this out and to and to improve the NHS. And that's what I want us to do together.'
The co-chairs of the BMA's resident doctors committee, Dr Melissa Ryan and Dr Nieuwoudt, said in a statement: 'The Health Secretary has been refusing to meet with us since he announced this year's disappointing pay award, so it's good to hear that he would now like to get round the table.
'We'll be expecting to start negotiations on July 8th, when our ballot will have closed and there will be no excuse not to meet.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
11 minutes ago
- The Sun
Warning as deadly ‘suitcase viruses' that destroy organs and trigger brain swelling spread across the UK and Europe
DEADLY viruses could be making their way to the UK on planes and in holidaymakers' suitcases, experts warn. They say international travel is fuelling a "concerning" rise in both chikungunya and oropouche, and the worst could be yet to come. 18 18 18 Simon Clarke, professor of cellular microbiology at the University of Reading, told The Sun: "As Brits develop more exotic tastes for travel to warmer places closer to the equator, we are increasingly likely to see unusual infections upon their return. "While oropouche is mainly found in the Amazon and chikungunya in sub-tropical regions, they are spreading. "Both have been detected in the United States and Europe, where sporadic outbreaks in France and Italy have occurred." Paul Hunter, a professor of medicine at the University of East Anglia, added: "There is a small risk of airport associated infections whereby infected mosquitoes arrive in the UK on board airplanes and then escape. "The spread of any infection into a previously unexposed population is always a matter for concern." Chikungunya is a virus spread by mosquito bites, the symptoms of which include a sudden fever and joint pain. Most people recover within two weeks, but the joint pain can last for months or even years, according to the UK Health Security Agency (UKHSA). In some cases, it is so bad it causes sufferers to "fold in half" or "become contorted" as they double over in agony. Serious complications are not common, but in rare cases the disease can cause organ damage and be fatal, particularly in very young or older people, or those with underlying health conditions. The latest report from the UKHSA shows there were 73 cases of chikungunya reported in England, primarily in London, between January and June 2025 - the highest number ever recorded. This compares to 27 cases for the same period last year. The majority were linked to travel to Sri Lanka, India and Mauritius. There is currently no risk of onward transmission of chikungunya, as the two species of mosquito that transmit the disease are not established in the UK. But experts fear cases could continue to rise with global travel and rising temperatures. Prof Clarke said: "Chikungunya is spread by mosquitoes, one of which, the tiger mosquito, has been detected in the South East of England. "It's worth emphasising the negative impact that global warming may have on a resilience to infections like this, which we've always taken for granted in the UK. "A warmer climate may mean that we have to take greater precautions at home against infections spread by insects." 18 Prof Hunter added: "We have seen local outbreaks of both dengue and chikungunya multiple times on the Mediterranean coasts of France, Italy and Spain over the past decade, and such events seem to be becoming more frequent. "Chikungunya outbreaks are less common than dengue, but when we do see them, they tend to be big, at least in Italy. "Both chikungunya and oropouche can occasionally be fatal. And the fact that locally-acquired infections are being reported from multiple locations this year is concerning. "There will be several more weeks before the mosquito season starts to tail off [so it could get worse]. "We will almost certainly see more cases in the UK, but at least for a few decades, these are all likely to have been acquired overseas." Chikungunya can be a nasty disease and we're seeing a worrying increase in cases among travellers returning to the UK Dr Philip VealUKHSA Chikungunya mainly occurs in Africa and southern Asia, although cases have been reported in Europe and parts of North America. This year, there have been outbreaks in the Americas and Asia, with surges on the Indian Ocean islands of Reunion, Mayotte and Mauritius. More than 10,000 people have also been struck down in China since June 2025. The majority of cases have been reported in Foshan, a city in the southern Guangdong province, where officials have since rolled out Covid-style lockdowns and been spraying insecticides in a desperate bid to stop the virus from spiralling out of control. At least 12 other cities in the southern Guangdong province have also reported infections, as well as Hong Kong and Taiwan. Since early 2025, there have been 240,000 cases and 90 deaths reported in 16 countries, according to the European Centre for Disease Prevention and Control (ECDC). 18 18 18 18 Two chikungunya vaccines are approved for use in the UK and are available to buy after an assessment at a private travel clinic. Travellers can stay safe by using insect repellent and covering their skin, especially at dawn and dusk. 'ESSENTIAL' PRECAUTIONS Dr Philip Veal, consultant in public health at UKHSA, said: "Chikungunya can be a nasty disease and we're seeing a worrying increase in cases among travellers returning to the UK. "While this mosquito-borne infection is rarely fatal, it can cause severe joint and muscle pain, headaches, sensitivity to light and skin rashes. "Thankfully symptoms usually improve within a few weeks, but joint pain may last for months or longer. "It is essential to take precautions against mosquito bites when travelling. "Simple steps, such as using insect repellent, covering up your skin and sleeping under insecticide-treated bed nets can greatly reduce the risk." 18 The UKHSA has also detected the first cases of oropouche in travellers coming to the UK from Brazil. The flu-like illness can cause a fever, headaches, joint pain, muscle pain, chills, nausea and vomiting. In serious cases, it can cause brain-swelling, specifically in the form of encephalitis and meningitis. Officials are urging anyone who becomes unwell after travel to affected areas, including parts of Central and South America and the Caribbean, to seek urgent medical advice. According to the World Health Organisation (WHO), before late 2023, oropouche was mostly reported near the Amazon rainforest area. It was dubbed 'sloth fever' as it circulates between primates, sloths and birds before occasionally being passed to humans by midges and mosquitoes. In 2024, Brazil, Bolivia, Colombia, Cuba, Guyana, Peru and the Dominican Republic reported locally transmitted cases of the disease. Travel-related cases are now cropping up across Europe. Francois Balloux, professor of computational systems biology and director of the UCL Genetics Institute, specialising in infectious diseases, said: "There seems to have been a marked increase of both chikungunya and oropouche cases in the parts of the world where they're endemic. "It is obviously a problem as both are unpleasant viruses. "Neither could circulate in the UK as their vectors are absent, but travellers are being infected overseas and returning home. "The number of cases in the UK could go up or down in the future." 18 18 18 18 The first imported cases of oropouche were reported in Europe in June and July 2024. There were 12 in Spain, five in Italy and two in Germany. All had a history of travel to Cuba or Brazil. Direct human-to-human transmission of the virus has not been documented so far, according to the ECDC. The prognosis for recovery is good and "fatal outcomes are extremely rare". There are no vaccines to prevent or specific medication to treat oropouche. The UKHSA report also shows a rise in travel-associated cholera cases in the UK, with eight cases in the first half of the year compared to just one in 2024. Most cases were linked with travel to India and Ethiopia. There was also a 67 per cent decrease in the number of dengue cases reported in England, Wales and Northern Ireland from January to June, and there were just four cases of zika virus during the period, down from nine in 2024. Oropouche virus: Everything you need to know Oropouche is a disease caused by Oropouche virus. It is spread through the bites of infected midges (small flies) and mosquitoes. Symptoms ARE similar to dengue and include: a headache, fever, muscle aches, stiff joints, nausea, vomiting, chills, or sensitivity to light. Severe cases may result in brain diseases such as meningitis. Symptoms typically start four to eight days after being bitten and last three to six days. Most people recover without long-term effects. There are no specific medications or vaccines available. Travellers heading to affected areas should take steps to avoid bug bites. The virus is endemic in many South American countries, in both rural and urban communities. Outbreaks are periodically reported in Brazil, Bolivia, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. Wear tops with long sleeves and long trousers, apply insect repellent regularly, and sleep under a mosquito net if you are not in enclosed, air-conditioned accommodation. Source: US Centre for Disease Control and Prevention 18 18 18 18
The Independent
40 minutes ago
- The Independent
Woman died after 10-minute power cut during heart surgery
A woman died during an operation after an unexpected power outage at Scunthorpe General Hospital meant doctors were unable to complete critical heart surgery until power was restored. Jean Dye, 77, was undergoing a procedure to treat heart disease on 7 September 2020, when a "sudden and unexpected" loss of electricity to the treatment room meant surgeons were unable to use vital equipment, the coroner's report states. The power loss came as the surgeons were aiming to repair a tear in an artery caused during the operation, something the coroner recognised as "a rare but recognised complication of the procedure". The outage, which lasted for 10 minutes, meant the surgical team could not use real-time x-rays which were required to insert the stents (mesh tubes which are inserted into blood vessels to hold them open). Once an engineer arrived and restored the power, the stenting was then completed. However, the report, by Paul Smith, senior coroner for Greater Lincolnshire, states that "Mrs Dye failed to recover and her death was confirmed." "On balance of probabilities, Mrs Dye would have survived but for the loss of electrical power," Mr Smith said. "No clear cause of that loss of power was identified," he said, adding that "a fault within the circuitry was suspected but not established to the required standard". The report also warns that the investigation revealed electrical systems in the hospital may still be cause for concern. "In my opinion there is a risk that future deaths could occur unless action is taken," Mr Smith said. "All staff at the scene were unaware of the cause of the loss of power, never having experienced such a situation previously, and an engineer was summoned to attend to reinstate the power, which he did." Despite this, the report found evidence for similar such outages nationally. "It is plainly something which can, and does, occur." "Had staff been aware of the exact cause of the loss of power on this occasion and had they had the opportunity to reset the circuit without the need to await the arrival of an engineer, who in turn had to attend a separate plant room, the downtime would likely have been significantly reduced." Mr Smith added: "There may well be future cases within which such fine margins are time critical." The report states that NHS England has a duty to respond to the issues raised in the report by 28 August 2025.
The Sun
an hour ago
- The Sun
Your ultimate guide to beat the Mounjaro price hike – from switching jabs to getting them FREE on the NHS
THE price of Mounjaro is set to soar, The Sun revealed yesterday - leaving slimmers desperate and worried at how they will afford the 'life-changing' drug. With the price hike looming on September 1, we reveal how to dodge the spiralling bills, getting your jabs for cheaper - or even free on the NHS - as well as the different side effects to be wary of. 2 The NHS has been giving Mounjaro prescriptions within GP practices since June. Private pharmacies boast 'no GP referral needed', with tantalising prices drawing in an estimated one million paying customers. Costs vary depending on the provider, jab and dosage, but are currently between around £120 and £220 per month. But that's all set to change, as the US-based maker of Mounjaro, Eli Lilly, told The Sun it will be increasing charges in Britain to 'address inconsistencies' with prices it commands from other western countries. The price the pharma giant charges pharmacies for a mid-range 5mg dose will nearly double from £92 to £180 from September 1. The maximum available dose, 15mg, will rise from £122 to £330. Eli Lilly claimed to have negotiated with big private suppliers to ensure the whole price increase is not passed on to patients - but with pharmacies already marking up jab prices, the public can expect to see the cost increase. It marks a huge blow for those for whom the jab offers a life-saving way out of obesity. The hefty price would affect those currently on the jabs, as well as those who had hoped to pay for them long-term to avoid weight regain. Toby Nicol, CEO at CheqUp, which has around 50,000 customers on weight loss jabs, said: 'This news will be disappointing for those who have achieved life-changing results with Mounjaro. 'This is particularly the case for those on higher doses who will likely see substantial rises in price." Weight Loss Jabs - Pros vs Cons Mounjaro has been dubbed the 'King Kong' of fat jabs because its success tops other brands, including Wegovy (also called Ozempic for type 2 diabetes), and Saxenda. Now, with people considering switching to Wegvoy, some providers appear to have hiked prices of the alternative jab that's similar to Ozempic, in response to the update. Mr Nicol, who says they have reduced the price of Wegovy on CheqUp, says: "Wegovy is a brilliant drug and that's why we don't want anyone to be priced out and think they have to take something which is unsafe. "Do not buy from the cowboys. If the price is to good to be true, it probably is." Dr Ralph Abraham, a diabetes and endocrinology specialist verified on Doctify, a healthcare review platform, says: 'There is no problem in switching from one drug to another. 'But in a world where the drugs are often not prescribed by experienced doctors, it then becomes difficult to know where side effects might lie.' Here, we answer the worries of readers and address how this could influence weight loss jabs and their success. CAN I SWITCH TO WEGOVY? IT depends who you ask. Mr Nicol says: "It's clinically acceptable to go from Mounjaro to Wegovy. We are developing our own switching plan. 'While Mounjaro remains the most effective treatment available, Wegovy is a more affordable option and is also clinically proven as a highly effective weight loss drug that has delivered incredible results for people who are on a weight loss journey. 'We are ready and able to provide advice to those who are looking to switch.' But Dr Suhail Hussain, a private GP verified on Doctify, believes this is likely to affect weight loss. 'There is no direct dose equivalent, so swapping between drugs is not possible,' he says. Wegovy is prescribed between 0.25mg and 2.4mg, while Mounjaro has doses between 2.5mg and 15mg. Dr Hussain said: 'The weight loss drugs are generally started at the lowest dose and titrated up. 'So if you were on mid-strength Mounjaro you would have to go onto the lowest strength Wegovy. 'There may also need to be a 'wash out' period to wean off one on to the other - which will again have impact on results." But Mr Nicol says: "It doesn't feel right to do that, it's like a game of snakes and ladders. "We'd be saying to people, for example, on 7.5mg of Mounjaro, that they shuold be transferring over to 1.7mg of Wegovy." Patients should receive clinically appropriate care, under supervision, that aligns with their individual health needs and personal circumstances, experts said. WHAT ARE THE RISKS OF SWITCHING TO WEGOVY? A USER would also need to adjust to the side effects of a new medicine. While these are relatively the same for either jab, there are slight differences. 'Mounjaro tends to be better tolerated in terms of GI side effects than Weygovy, so you may experience more nausea or vomiting etc,' says Dr Hussain. The 'very common' side effects of both Mounjaro and Wegovy are nausea, diarrhoea, vomiting and constipation, according to Asda Online Doctor. But Wegovy also says headache, stomach pain and feeling weak or tired are very common. WILL I LOSE AS MUCH WEIGHT ON WEGOVY? THE active ingredient in Wegovy is semaglutide, while in Mounjaro it is tirzepatide. Both work in a very similar way on the body. Dr Hussain says: 'The two drugs work in a similar way (both are GLP-1 receptor agonists) but have some important differences. 'Mounjaro is a dual GIP + GLP-1 receptor agonist, while Wegovy is GLP-1 agonist only. 'Therefore, there may be a difference in impact on appetite suppression and hence subsequent weight loss.' GLP-1 is a natural hormone released in your gut when you eat. By activating GLP-1 receptors, Wegovy helps slow down stomach emptying and control blood sugar levels, helping with fullness and sending a message to the brain to reduce food intake. Mounjaro does this too, but also mimics the hormone GIP, which also plays a role in blood sugar regulation and appetite. It's dual-action may be why Mounjaro is the preferred jab of choice for weight loss. 2 Mounjaro can help you lose around 21 per cent of your body weight, while Wegovy can help you lose 14.9 per cent. In one trial of Mounjaro, the SURMOUNT-1 trial of tirzepatide in non-diabetic patients over 72 weeks, people lost up to 22.5 per cent of their body weight while taking the highest maintenance dose. More than 89 per cent of people lost at least five per cent of their starting weight. STEP-1, a 68-week clinical trial carried out to study the weight loss effects of semaglutide (Wegovy), found that people lost up to 17 per cent of their body weight after taking the 2.4mg maintenance dose. Up to 85 per cent of patients lost at least five per cent of their starting weight. Mr Nicol said: "Mounjaro is a Ferrari, Wegovy is a Porsche, and diet and exercise is a horse and cart." HOW CAN I GET THE JAB CHEAPER? SWITCHING to Wegovy might save you money - if your provider hasn't increased its prices. Below is a box showing the price of the highest dose of Wegovy and Mounjaro - but because the doses are not comparable, it's difficult to also compare their prices. Eli Lilly claimed it is negotiating with providers so that the whole increase is not passed on to patients. Mr Nicol said: 'At CheqUp we are determined to support our patients as best we can – and can announce today that despite these price rises we will not raise prices for those who are on the two lowest doses of Mounjaro. 'We will also not pass on the full cost of the price rise for those on higher doses.' HOW CAN I GET MOUNJARO FREE ON THE NHS? IT was a game-changing moment when the NHS announced it would be prescribing weight loss jabs for free. You need to fit a strict set of criteria to be eligible, but the initial rollout is extremely limited to just 22,000 patients over the next three years. There are 3.4million people in England who would qualify for treatment under the NICE eligibility criteria. The NHS says you'll only be prescribed semaglutide (Wegovy) if you have health problems due to your weight and you have a BMI of either: 35 or more, or 32.5 or more if you're of Asian, Chinese, Middle Eastern, Black African or African-Caribbean origin 30 to 34.9, or 27.5 to 32.4 if you're of Asian, Chinese, Middle Eastern, Black African or African-Caribbean origin, and you meet other criteria to be treated by a specialist weight management service Only a specialist weight management service can prescribe semaglutide. You may be eligible for tirzepatide (Mounjaro) from a GP if you have: A BMI of 40 or more And have at least four of these weight-related health conditions: type 2 diabetes high blood pressure (hypertension) heart disease (cardiovascular disease) abnormal blood fats (dyslipidaemia) obstructive sleep apnoea A weight management service or GP can prescribe tirzepatite. CAN I GET AROUND THE POSTCODE LOTTERY? THERE is a 'postcode lottery' of prescription, so whether you can access the drugs depends largely on where you live. Shockingly, as little as eight out of 42 NHS Integrated Health Boards are prescribing the jabs, according to Sky News. Can you get around it? 'No,' says Dr Hussain. The NHS says you can check with your local Integrated Care Board to see if you are eligible for an assessment. Some GP practices have begged patients to stop requesting it from them. For example, a statement from Dr Khan's Practice in Clayton, Manchester, read: 'Tirzepatide (Mounjaro) is not currently available anywhere in Greater Manchester, including GP practices, hospitals or specialist weight management services. 'Please do not contact us to request it – you'll be contacted directly if you are eligible when the service becomes available in the area. 'Dr Khans Practice are not prescribing GLP-1 medications for weight loss until a service agreement is in place with Manchester ICB which is currently under review.' The 7 fat jab mistakes stopping you losing weight WHILE weight loss jabs have been hailed as a breakthrough in helping tackle Britain's obesity crisis, some users say they're missing out on their waist-shrinking powers - and it could be down to some simple mistakes... POOR PENMANSHIP Many people don't correctly use the injection pen, according to Ana Carolina Goncalves, a pharmacist at Pharmica in Holborn, London. Make sure to prime your weight loss pen correctly, as per the instructions. If nothing comes out, try again, and if it still doesn't work, switch the needle or ask a pharmacist for help. It's also recommended to rotate injection sites between the abdomen, thigh and upper arm to avoid small lumps of fat under the skin. TIME IS OF THE ESSENCE Make sure you're using the jabs on the most effective day of your schedule. For example, taking the jab right before a takeaway or party won't stop you from indulging, says Jason Murphy, head of pharmacy and weight loss expert at Chemist4U. Weight loss injections need time to build up in your system, so if you're planning for a heavier weekend, inject your dose mid-week. MAKING A MEAL OF IT You may not feel the urge to overeat at mealtimes due to the jabs. But skipping meals altogether can backfire, says Dr David Huang, director of clinical innovation at weight loss service Voy. If a person is extremely malnourished, their body goes into emergency conservation mode, where their metabolism slows down. FOOD FOR THOUGHT A key mistake using weight loss jabs is not eating the right foods. As well as cutting out sugary drinks and alcohol, Dr Vishal Aggarwal, Healthium Clinics recommends focusing on your protein intake. DE-HYDRATION STATIONS Dehydration is a common side effect of weight loss injections. But it's important to say hydrated in order for your body to function properly. Dr Crystal Wyllie, GP at Asda Online Doctor, says hydration supports metabolism, digestion, and can reduce side effects like headaches, nausea and constipation. MOVE IT, MOVE IT It can be easy to see the jabs as a quick fix, but stopping exercising altogether is a mistake, says Mital Thakrar, a pharmacist from Well Pharmacy. Exercise helps maintain muscle mass and help shape the body as you lose weight, which may be crucial if you're experiencing excess skin. QUIT IT While there's the tendency to ditch the jabs as soon as you reach your desired weight, stopping them too soon can cause rapid regain. Mr Thakrar recommends building habits like healthier eating during treatment for sustaining results.
